Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001721097 | SCV000223313 | likely benign | not provided | 2019-04-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000242415 | SCV000319046 | likely benign | Cardiovascular phenotype | 2016-06-06 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000547992 | SCV000627564 | benign | Long QT syndrome | 2024-01-29 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001721097 | SCV002048908 | benign | not provided | 2022-02-28 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003398877 | SCV004121852 | benign | not specified | 2023-10-19 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001721097 | SCV004132357 | likely benign | not provided | 2023-01-01 | criteria provided, single submitter | clinical testing | CACNA1C: BP4, BP7 |
Breakthrough Genomics, |
RCV001721097 | SCV005213580 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV003965227 | SCV004776628 | likely benign | CACNA1C-related disorder | 2024-02-08 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |